Key points for investors:
- Strategic collaboration: Palatin executed a research collaboration, license and patent assignment agreement with Boehringer Ingelheim (BI) for retinal disease candidates. Upfront and near-term non-dilutive payments received include ~€2.0M (~$2.3M) upfront and a €5.5M (~$6.5M) research milestone; the deal includes up to ~€12.5M (~$14.5M) additional near-term research milestones, up to ~€260M (~$307M) in development/regulatory/commercial milestones, and tiered royalties on future sales.
- Financial results and funding: Q1 FY2026 revenue was ~$8.8M (entirely from the BI agreement). Operating expenses declined to $4.2M from $7.8M year-over-year. Net income for the quarter was $4.7M vs. a $7.8M loss a year ago. Cash and equivalents were $1.3M at 9/30/25 (does not reflect an October $6.5M BI milestone or $16.9M net proceeds from an $18.2M underwritten public offering closed 11/12/25). The offering restored NYSE American listing (ticker PTN) and removed the going-concern qualification; management expects cash runway beyond the quarter ending 12/31/2026.
- Equity/warrants detail: The upsized public offering raised gross proceeds associated with common shares and Series J/K warrants. Series J warrants are tied to FDA IND acceptance for an in-house obesity compound (shorter exercise window); Series K are longer-dated. Company expects potential additional proceeds if Series J warrants are exercised upon reaching IND acceptance.
- Development pipeline and timelines: Primary R&D focus is selective melanocortin-4 receptor (MC4R) agents for syndromic/genetic obesity (e.g., hypothalamic obesity). PL-7737 (oral MC4R-selective small molecule) is undergoing IND-enabling work (toxicology, cGMP) and is on track for an IND filing in H1 2026; initial clinical studies (SAD/MAD in healthy obese and hypothalamic patients) are planned with data expected in H2 2026. Long-acting MC4R peptides are expected to enter IND-enabling studies in H1 2026 and first-in-human in H2 2026. Key claimed product differentiators: high selectivity for MC4R over MC1R (to reduce hyperpigmentation risk) and flat/extended PK to minimize exposure spikes and GI side effects.
- Business-development strategy: Management intends to out-license several non-core MC programs (ocular, inflammatory bowel disease, kidney disease). The BI deal is presented as validation of the platform and will inform further licensing efforts.
- Near-term catalysts: IND filing for PL-7737 (H1 2026), initial clinical data for PL-7737 and peptide programs (H2 2026), potential near-term BI research milestones (~$14.5M reported as possible and guidance of ~ $15M near-term development milestones within ~12 months), and any further out-licensing deals.
- Risks/considerations: Clinical and regulatory risks remain (IND acceptance, clinical efficacy/safety), milestone/warrant exercise is not guaranteed, and prior cash levels were low prior to October/November inflows. Investors should monitor IND acceptance timing, clinical data readouts in H2 2026, milestone receipts from BI, and any further licensing transactions.
Sign In
Buy PTN
